CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

PHASE3TerminatedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

August 26, 2022

Primary Completion Date

February 26, 2024

Study Completion Date

February 26, 2024

Conditions
Chronic Kidney DiseasesPruritus
Interventions
DRUG

Difelikefalin 1 mg Oral Tablet

Difelikefalin 1 mg medication taken orally 1 time/day

DRUG

Placebo Oral Tablet

Placebo tablet taken orally 1 time/day

Trial Locations (75)

1872

Cara Therapeutics Study Site, Sarandí

2900

Cara Therapeutics Study Site, San Nicolás

10016

Cara Therapeutics Study Site, New York

15405

Cara Therapeutics Study Site, Ferrol

27100

Cara Therapeutics Study Site, Pavia

29118

Cara Therapeutics Study Site, Orangeburg

31520

Cara Therapeutics Study Site, Brunswick

33014

Cara Therapeutics Study Site, Miami Lakes

33016

Cara Therapeutics Study Site, Miami Lakes

33032

Cara Therapeutics Study Site, Miami

33331

Cara Therapeutics Study Site, Weston

41124

Cara Therapeutics Study Site, Modena

77476

Cara Therapeutics Study Site, Sugar Land

91324

Cara Therapeutics Study Site, Northridge

C1425DES

Cara Therapeutics Study Site, Ciudad Autonoma de Buenos Aire

W3400AMZ

Cara Therapeutics Study Site, Corrientes

B1824KAJ

Cara Therapeutics Study Site, Lanús

Unknown

Cara Therapeutics Study Site, Mar del Plata

Cara Therapeutics Study Site, Adelaide

Cara Therapeutics Study Site, Camperdown

Cara Therapeutics Study Site, Concord

Cara Therapeutics Study Site, Gosford

Cara Therapeutics Study Site, Kogarah

Cara Therapeutics Study Site, Launceston

Cara Therapeutics Study Site, Liverpool

Cara Therapeutics Study Site, Melbourne

Cara Therapeutics Study Site, Saint Albans

Cara Therapeutics Study Site, Westmead

Cara Therapeutics Study Site, Belo Horizonte

Cara Therapeutics Study Site, Salvador

Cara Therapeutics Study Site, São Bernardo do Campo

Cara Therapeutics Study Site, São José do Rio Preto

Cara Therapeutics Study Site 2, São Paulo

Cara Therapeutics Study Site, São Paulo

Cara Therapeutics Study Site, Dobrich

Cara Therapeutics Study Site, Gabrovo

Cara Therapeutics Study Site, Montana

Cara Therapeutics Study Site, Plovdiv

Cara Therapeutics Study Site, Heilbronn

Cara Therapeutics Study Site, Kaiserslautern

Cara Therapeutics Study Site, Baja

Cara Therapeutics Study Site, Budapest

Cara Therapeutics Study Site, Kistarcsa

Cara Therapeutics Study Site, Pécs

Cara Therapeutics Study Site, Florence

Cara Therapeutics Study Site, Roma

Cara Therapeutics Study Site, Aguas Calientes

Cara Therapeutics Study Site, Durango

Cara Therapeutics Study Site, Guadalajara

Cara Therapeutics Study Site, Mérida

Cara Therapeutics Study Site, Golub-Dobrzyń

Cara Therapeutics Study Site, Katowice

Cara Therapeutics Study Site 2, Krakow

Cara Therapeutics Study Site, Krakow

Cara Therapeutics Study Site, Lodz

Cara Therapeutics Study Site, Szczecin

Cara Therapeutics Study Site, Wroclaw

Cara Therapeutics Study Site, Bucharest

Cara Therapeutics Study Site, Oradea

Cara Therapeutics Study Site, Timișoara

Cara Therapeutics Study Site, Daegu

Cara Therapeutics Study Site 2, Goyang-si

Cara Therapeutics Study Site, Goyang-si

Cara Therapeutics Study Site, Seoul

Cara Therapeutics Study Site, Badalona

Cara Therapeutics Study Site, Barcelona

Cara Therapeutics Study Site, Madrid

Cara Therapeutics Study Site, Palma de Mallorca

Cara Therapeutics Study Site 2, Valencia

Cara Therapeutics Study Site, Valencia

Cara Therapeutics Study Site, Vitoria-Gasteiz

89227-680

Cara Therapeutics Study Site, Joinville

09090-790

Cara Therapeutics Study Site, São Paulo

03080

Cara Therapeutics Study Site, Seoul

04009

Cara Therapeutics Study Site, Almería

Sponsors
All Listed Sponsors
lead

Cara Therapeutics, Inc.

INDUSTRY